🚀 VC round data is live in beta, check it out!
Oramed Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Oramed Pharmaceuticals and similar public comparables like Milestone Pharmaceuticals, Cardiff Oncology, Abionyx Pharma, Connect Biopharma and more.
Oramed Pharmaceuticals Overview
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
Founded
2002
HQ
Employees
13
Website
Sectors
Financials (LTM)
EV
$2M
Oramed Pharmaceuticals Financials
Oramed Pharmaceuticals reported last 12-month revenue of $2M.
In the same LTM period, Oramed Pharmaceuticals generated — in gross profit and $54M in net income.
Revenue (LTM)
Oramed Pharmaceuticals P&L
In the most recent fiscal year, Oramed Pharmaceuticals reported revenue of — and EBITDA of ($15M).
Oramed Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 0% | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | ($15M) | XXX | XXX | XXX |
| EBIT Margin | (620%) | XXX | — | XXX | XXX | XXX |
| Net Profit | $54M | XXX | ($19M) | XXX | XXX | XXX |
| Net Margin | 2700% | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Oramed Pharmaceuticals Stock Performance
Oramed Pharmaceuticals has current market cap of $136M, and enterprise value of $2M.
Market Cap Evolution
Oramed Pharmaceuticals' stock price is $3.41.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2M | $136M | 0.0% | XXX | XXX | XXX | $-0.48 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOramed Pharmaceuticals Valuation Multiples
Oramed Pharmaceuticals trades at 0.9x EV/Revenue multiple, and (0.1x) EV/EBITDA.
EV / Revenue (LTM)
Oramed Pharmaceuticals Financial Valuation Multiples
As of March 21, 2026, Oramed Pharmaceuticals has market cap of $136M and EV of $2M.
Equity research analysts estimate Oramed Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Oramed Pharmaceuticals has a P/E ratio of 2.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $136M | XXX | $136M | XXX | XXX | XXX |
| EV (current) | $2M | XXX | $2M | XXX | XXX | XXX |
| EV/Revenue | 0.9x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.1x) | XXX | XXX | XXX |
| EV/EBIT | (0.2x) | XXX | (0.1x) | XXX | XXX | XXX |
| P/E | 2.5x | XXX | (7.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Oramed Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Oramed Pharmaceuticals Margins & Growth Rates
Oramed Pharmaceuticals' revenue in the last fiscal year declined by (100%).
Oramed Pharmaceuticals' revenue per employee in the last FY averaged $0.2M.
Oramed Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (303%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 320% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 300% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Oramed Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Milestone Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Cardiff Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Abionyx Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Connect Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Shield Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oramed Pharmaceuticals M&A Activity
Oramed Pharmaceuticals acquired XXX companies to date.
Last acquisition by Oramed Pharmaceuticals was on XXXXXXXX, XXXXX. Oramed Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Oramed Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOramed Pharmaceuticals Investment Activity
Oramed Pharmaceuticals invested in XXX companies to date.
Oramed Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Oramed Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Oramed Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Oramed Pharmaceuticals
| When was Oramed Pharmaceuticals founded? | Oramed Pharmaceuticals was founded in 2002. |
| Where is Oramed Pharmaceuticals headquartered? | Oramed Pharmaceuticals is headquartered in United States. |
| How many employees does Oramed Pharmaceuticals have? | As of today, Oramed Pharmaceuticals has over 13 employees. |
| Who is the CEO of Oramed Pharmaceuticals? | Oramed Pharmaceuticals' CEO is Nadav Kidron. |
| Is Oramed Pharmaceuticals publicly listed? | Yes, Oramed Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of Oramed Pharmaceuticals? | Oramed Pharmaceuticals trades under ORMP ticker. |
| When did Oramed Pharmaceuticals go public? | Oramed Pharmaceuticals went public in 2004. |
| Who are competitors of Oramed Pharmaceuticals? | Oramed Pharmaceuticals main competitors are Milestone Pharmaceuticals, Cardiff Oncology, Abionyx Pharma, Connect Biopharma. |
| What is the current market cap of Oramed Pharmaceuticals? | Oramed Pharmaceuticals' current market cap is $136M. |
| What is the current revenue of Oramed Pharmaceuticals? | Oramed Pharmaceuticals' last 12 months revenue is $2M. |
| What is the current EV/Revenue multiple of Oramed Pharmaceuticals? | Current revenue multiple of Oramed Pharmaceuticals is 0.9x. |
| Is Oramed Pharmaceuticals profitable? | Yes, Oramed Pharmaceuticals is net-income-positive (as of the last 12 months). |
| What is the current net income of Oramed Pharmaceuticals? | Oramed Pharmaceuticals' last 12 months net income is $54M. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.